This was a clinical trial in HIV infected patients with tuberculosis. The study assessed
whether the addition of prednisolone, a type of steroid medication, to the standard treatment
for tuberculosis improved immune and viral outcomes in the patients. The study demonstrated
that prednisolone increased the CD4 cell count as was hoped, but the beneficial effect was
short-lived and was gone within 4 months of stopping therapy. Therefore, the use of
prednisolone for tuberculosis in HIV infected patients is not recommended at this time.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)